Related Experiment Video
Updated: Jun 9, 2026
Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma
Published on: January 19, 2024
The Efficacy and Safety of Radiofrequency Microneedling for Melasma: A Systematic Review and Qualitative Evidence
Abstract:
Melasma is a chronic, relapsing hyperpigmentation disorder that is difficult to treat, particularly in Fitzpatrick skin types III-V, where energy-based devices frequently induce postinflammatory hyperpigmentation (PIH). Radiofrequency microneedling (RFMN) has emerged as a promising alternative because it targets dermal pathology while minimizing epidermal injury. Systematically evaluate the efficacy, safety, and mechanistic rationale of RFMN for melasma. A PRISMA 2020 compliant search of PubMed, Embase, Cochrane CENTRAL, and LILACS (2014-2025) identified clinical studies evaluating RFMN alone or in combination therapies. Risk of bias was assessed using Joanna Briggs Institute tools. Owing to clinical and methodological heterogeneity, a qualitative synthesis was performed. Across 12 included studies, RFMN consistently improved Melasma Area and Severity Index (MASI) or modified MASI scores and melanin indices, with effects maintained up to 6 months. Histological evidence demonstrated reductions in dermal senescence markers and partial restoration of basement-membrane integrity. RFMN also showed a favorable safety profile, with a low incidence of PIH in darker phototypes. Combination treatment, particularly with low-fluence Q-switched Nd:YAG laser produced greater pigment reduction than monotherapy. RFMN is an effective and safe modality for melasma, offering advantages over pigment-directed lasers by addressing dermal mechanisms and limiting PIH risk. It may serve as a first-line energy-based therapy. Level of Evidence:3 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
Insights
Radiofrequency microneedling (RFMN) effectively treats melasma, even in darker skin types, by targeting dermal issues with minimal epidermal damage. This method shows sustained improvement and a favorable safety profile, making it a promising therapeutic option.
Area of Science:
- Dermatology
- Aesthetic Medicine
- Regenerative Medicine
Background:
- Melasma is a persistent hyperpigmentation disorder challenging to treat, especially in Fitzpatrick skin types III-V.
- Traditional energy-based treatments risk postinflammatory hyperpigmentation (PIH) in darker skin.
- Radiofrequency microneedling (RFMN) offers a novel approach by targeting dermal pathology with reduced epidermal injury.
Purpose of the Study:
- To systematically evaluate the efficacy, safety, and mechanistic basis of RFMN for melasma treatment.
- To synthesize evidence from clinical studies on RFMN's use as monotherapy or combination therapy.
- To assess RFMN's potential as a first-line energy-based treatment for melasma.
Main Methods:
- A PRISMA 2020 compliant systematic review of studies from 2014-2025.
- Searches conducted in PubMed, Embase, Cochrane CENTRAL, and LILACS.
- Qualitative synthesis due to clinical and methodological heterogeneity; risk of bias assessed using Joanna Briggs Institute tools.
Main Results:
- RFMN consistently improved Melasma Area and Severity Index (MASI) scores and melanin indices across 12 studies.
- Treatment effects were maintained for up to 6 months post-therapy.
- Histological findings indicated reduced dermal senescence and improved basement membrane integrity; PIH incidence was low in darker skin types.
- Combination therapy, especially with Q-switched Nd:YAG laser, enhanced pigment reduction.
Conclusions:
- RFMN is an effective and safe modality for melasma treatment, particularly beneficial for Fitzpatrick skin types III-V.
- It offers advantages over pigment-directed lasers by addressing dermal mechanisms and minimizing PIH risk.
- RFMN may be considered a viable first-line energy-based therapy for melasma.
